FDA Determines Regulatory Review Period for SYLVANT Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of SYLVANT, a human biological product, following the submission of relevant applications to the U.S. Patent and Trademark Office (USPTO).